European Pharmaceutical Pricing & Reimbursement (2011)

SMi present their 17th annual conference on

European Pharmaceutical Pricing & Reimbursement

31st October – 1st November 2011
Basel, Switzerland
 

2011 has brought with it huge changes to the health care landscape - the global economic crisis and rising healthcare costs have caused governments to take cautious approaches towards pricing and reimbursement (P&R) for pharmaceuticals.

With aging and expanding populations, improving standards of living has meant there has been a significant burden on the healthcare systems. Emerging markets are also finding it challenging to meet the increasing expectations for healthcare, despite rapid economic growth. This event will therefore review the key challenges and developments in the emerging markets, established markets and the US with their impact on international healthcare

Key topics include: 

EU Policy challenges in access to medicine in Europe HTA agency policy and practice globally: Comparing and contrasting different models Germany's AMNOG: Facts and consequences               Lessons learnt from international experience of VBP The access marketing mix for launch products Orphan drug P&R in Europe: Are the payors biting back?